EUVIMEDEUVIMED entdecken
Crossref

Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer

Daniel Walden, Felipe Batalini iD, Cody Eslinger iD, Yoshiaki Nakamura iD, Andrew Krueger, Sachin Kumar Deshmukh, Kazunori Yamanaka, Christina Wu iD, Mohamad Basam Sonbol iD, Sharon Wu, Joanne Xiu, John Strickler iD und 5 weitere

JCO Precision Oncology · 2026-04 · 10 (4)

DOI: 10.1200/po-25-00452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-04. Verfasst von Daniel Walden und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Homologous Recombination. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Homologous recombination deficiency (HRD) is a key determinant of sensitivity to DNA-damaging agents; however, its genomic characterization in colorectal cancer (CRC) remains limited. This study investigated whether low RNA expression of homologous recombination (HR) genes identifies patients with metastatic CRC who derive survival benefit from oxaliplatin- or irinotecan-based therapy. METHODS A total of 22,957 metastatic CRC samples were subjected to DNA and RNA sequencing (Caris Life Sciences, Dallas, TX). Patients with microsatellite instability–high or pathogenic HR gene mutations were excluded to define a HR-proficient cohort. Overall survival (OS) was compared between patients with low (bottom 25%) versus high (top 25%) RNA expression of HR genes after oxaliplatin or irinotecan exposure. Validation was performed in the PARADIGM phase III trial cohort (n = 262) of first-line modified fluorouracil, leucovorin, and oxaliplatin-treated patients with available RNAseq data. RESULTS In the discovery cohort, low expression of core HR genes correlated with significantly longer OS after oxaliplatin or irinotecan exposure, specifically RAD51 (43.0 v 36.3 months; P < .005) and BLM (42.9 v 34.2 months; P < .005). Similar associations were observed for RAD51 (28.1 v 22.9 months; P = .02) and BLM (29.1 v 23.2 months; P < .005) in irinotecan-treated patients. In the PARADIGM validation cohort, low BLM expression was associated with improved OS (41.5 v 22.4 months; HR = 0.52; P = .002), whereas RAD51 showed a favorable but nonsignificant trend. These findings remained significant after adjustment for treatment arm, tumor sidedness, and metastatic burden. CONCLUSION Low BLM RNA expression is associated with improved survival after treatment with DNA-damaging agents, whereas low RAD51 expression shows a favorable but nonsignificant trend. These findings are exploratory and suggest that RNA-based HR gene expression may warrant further investigation as a potential prognostic biomarker in metastatic CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsHomologous RecombinationHumansIrinotecanFemaleOxaliplatinMaleMiddle AgedRad51 RecombinaseRecQ HelicasesAged

Substanzen

IrinotecanOxaliplatinBloom syndrome proteinRad51 RecombinaseRAD51 protein, humanRecQ Helicases

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Mayo Clinic, Phoenix, AZ.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Oncology Therapeutic Area Unit, Takeda Pharmaceutical Company Ltd, Kanagawa, Japan.
  • Caris Life Science, Phoenix, AZ.
  • Duke University Medical Center, Durham, NC.
  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

ORCID-Profile: Felipe Batalini, Cody Eslinger, Yoshiaki Nakamura, Christina Wu, Mohamad Basam Sonbol, John Strickler, Mitesh J Borad, Daniel Ahn, Kei Muro, Takayuki Yoshino, Tanios Bekaii-Saab

Zitieren

APA

Walden, D., Batalini, F., Eslinger, C., Nakamura, Y., Krueger, A., Deshmukh, S. K., Yamanaka, K., Wu, C., Sonbol, M. B., Wu, S., Xiu, J., Strickler, J., Borad, M. J., Ahn, D., Muro, K., Yoshino, T., & Bekaii-Saab, T. (2026). Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer. JCO Precision Oncology, 10(4). https://doi.org/10.1200/po-25-00452

Vancouver

Walden D, Batalini F, Eslinger C, Nakamura Y, Krueger A, Deshmukh SK, et al. Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer. JCO Precision Oncology. 2026;10(4). doi:10.1200/po-25-00452

BibTeX
@article{Walden2026,
  author = {Walden, Daniel and Batalini, Felipe and Eslinger, Cody and Nakamura, Yoshiaki and Krueger, Andrew and Deshmukh, Sachin Kumar and Yamanaka, Kazunori and Wu, Christina and Sonbol, Mohamad Basam and Wu, Sharon and Xiu, Joanne and Strickler, John and Borad, Mitesh J and Ahn, Daniel and Muro, Kei and Yoshino, Takayuki and Bekaii-Saab, Tanios},
  title = {Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/po-25-00452}
}
Kostenlos starten →